强大的微粒配方可改善多个医疗保健系统中败血症的全身皮质类固醇治疗
Younes Louaguenouni1, Qinglin Wang1, Thomas Baticle1
1Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400, Orsay, France.
概括
这项研究开发了基于DSPE-PEG的细胞来输送德甲,通过扩大药物循环和向免疫细胞来改善败血症治疗. 这种细胞输送系统为传统的皮质类固醇治疗提供了更安全,更有效的替代方案.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 免疫学 免疫学 免疫学
背景情况:
- 败血症是一种危急的疾病,每年造成数百万人的死亡,通常用德甲等皮质类固醇治疗.
- 目前用于败血症的皮质类固醇治疗有不良影响,限制了它们的临床效用.
- 需要改进药物输送系统,以提高甲在败血症管理中的有效性和安全性.
研究的目的:
- 开发一种可扩展,具有成本效益和冷干燥兼容的细胞配方,用于德克萨米他的输送.
- 通过延长其血液循环时间和向先天免疫细胞来改善德克萨米他的体内疗效.
- 在临床前的败血症模型中评估甲载菌体的治疗潜力.
主要方法:
- 基于DSPE-PEG的基被设计用于封装德甲.
- 评估了微粒的物理化学特性,稳定性和体外释放动力学.
- 活体疗效被评估在小鼠内毒性和结结和穿孔败血症模型中.
- 进行了生物分布和活体成像,以分析药物循环和免疫细胞向.
主要成果:
- 含德甲的小粒体表现出强大的物理化学特性和受控释放.
- 在两种不同的小鼠败血症模型中,细胞配方显著提高了生存率.
- 生物分布研究证实了长时间的血液循环和免疫细胞的优先积累.
- 与可溶性药物形式相比,观察到素甲的效率提高.
结论:
- 开发的基于DSPE-PEG的细胞系统提供了一个强大的平台,用于在败血症中输送德甲.
- 这种纳米载体系统通过改善药理动力学和免疫细胞向来增强德克萨米他的治疗效果.
- 菌根配方是一个有前途的,更安全,更有效的替代方案,用于治疗败血症的传统皮质类固醇治疗.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
123
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
123
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
183
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
183
01:29Inflammatory Bowel Disease IV: Pharmacological Management
83
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
83
01:27Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K